FIRST BERLIN Equity Research

Size: px
Start display at page:

Download "FIRST BERLIN Equity Research"

Transcription

1 FRST BERLN Equity Research NTERSHOP COMMUNCATONS AG GERMANY / TECHNOLOGY Primary Exchange: Frankfurt Bloomberg symbol: SH2 SN: DE000A0EPUH1 NTERSHOP COMMUNCATONS AG OVERVEW 15 December 2010 RATNG: Buy PRCE TARGET: 2.60 RETURN POTENTAL: 29.9% RSK RATNG: High BOARD COMPROMSE REACHED; SHAREHOLDER GROUP TO REMAN ACTVE GS s Attempted Silent Takeover of ntershop has Suffered a Setback. The Extraordinary General Meeting of ntershop took place yesterday in Jena. The meeting had been called by strategic partner and largest shareholder, GS, which sought to take all seats on ntershop s Supervisory Board (SB). As indicated in our previous research on the company, we expected that minority shareholders would try to block GS s move. This expectation has materialized. GS has conceded the Supervisory Board Chairman seat. Dr. Herbert May will remain ntershop s Chairman. This outcome had been negotiated ahead of the EGM between GS and a shareholder group led by Mr. Roland Klauss. Effectively, the only change to the SB was the appointment of Michael R. Conn, GS s CFO, in place of Günter Lorenz. Thus, GS currently control 2 out 3 Supervisory Board seats. Shareholder group to remain active. Mr. Klauss was able to rally EGM shareholders representing an aggregate stake of above 20%. Combined with press coverage and analyst research published in the run-up to the event, this contributed to record high shareholder turn-out of 50.3% at the meeting, which lasted nearly 7 hours. Mr. Klauss gave clear indication that the shareholder group will remain active. Discussions with major investors are underway as the activist group tries to increase its stake in ntershop further. The EGM outcome is positive for ntershop s stock price. GS will retain its stake in ntershop. GS wishes to control the development of Enfinity Suite 7, which is a critically important project for both companies. The activist shareholder group is also seeking to bring new strategic investors into the picture. This implies short-term upward pressure on ntershop s stock. We maintain our BUY rating and 2.60 price target on ntershop. FNANCAL HSTORY & PROJECTONS E 2011E 2012E Revenue ( m) Y-o-y growth na 4.5% 13.0% 20.0% 12.5% 13.8% EBT ( m) EBT margin -7.2% 6.7% 6.3% 4.5% 7.1% 8.8% Net income ( m) EPS (diluted) ( ) P/E (x) na DPS ( ) Yield 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% FCF ( m) Net gearing 1.4% 7.6% 4.2% 12.7% 13.0% 13.5% Liquid assets ( m) ,42 26,26 RSKS Risks include, but are not limited to, market share losses, unfavorable macroeconomic developments, and management churn. COMPANY PROFLE ntershop is one of the pioneers of the e- commerce solutions market. ntershop has over 300 customers. The company's target customer base includes mid-market and large enterprise companies. Typical implementation projects include online retail store development, supply chain integration, and online marketing campaigns. TRADNG DATA Closing price ( ) 2.00 Shares outstanding 29.12m Market capitalisation 58.27m 52-week range 1.44/2.20 Avg. vol. (12-mos.) 57,826 STOCK OVERVEW 2,4 2,2 2,0 1,8 1,6 1,4 1,2 Dec 09 Mar 10 Jun 10 Sep 10 ntershop Communications AG COMPANY DATA (as of 30 September 2010) Liquid assets Current assets ntangible assets Total assets Current liabilities Shareholders equity SHAREHOLDERS NMDP ndex GS Commerce, nc. 27.2% Free float 72.8% m 23.42m 8.87m 33.74m 7.78m 23.04m Analyst: Tsvetan Kintisheff, Tel. +49 (0)

2 NCOME STATEMENT ANALYSS All figures in ' A 2008A 2009A 2010E 2011E 2012E Revenues 26,911 28,118 31,777 38,132 42,900 48,800 Cost of goods sold 14,879 16,713 16,866 22,584 24,855 27,438 Gross Profit 12,032 11,405 14,911 15,548 18,045 21,363 SG&A 9,428 7,105 8,355 8,963 9,438 10,736 R&D 2,977 1,228 4,275 4,924 5,577 6,344 Other Operating ncome/expense 1,572 1, Operating income -1,945 1,871 2,000 1,701 3,030 4,283 Net financial result ncome before income taxes and minority interests -2,162 1,754 2,135 1,704 3,030 4,283 ncome taxes Minority interests Net income / loss -2,033 1,503 2,089 1,619 2,727 3,854 EPS Diluted EPS EBTDA ,346 3,765 3,984 5,530 7,283 Ratios Gross margin 44.7% 40.6% 46.9% 40.8% 42.1% 43.8% EBT-Margin -7.2% 6.7% 6.3% 4.5% 7.1% 8.8% EBTDA margin -3.7% 8.3% 11.8% 10.4% 12.9% 14.9% Net ncome Margin -7.6% 5.3% 6.6% 4.2% 6.4% 7.9% Tax Rate n.m. 14.3% 20.0% 10.0% 10.0% 10.0% Expenses as % of revenues SG&A 35.0% 25.3% 26.3% 23.5% 22.0% 22.0% R&D 11.1% 4.4% 13.5% 12.9% 13.0% 13.0% Other Operating ncome/expense 5.8% 4.3% 0.9% -0.1% 0.0% 0.0% Y-Y Growth Total revenues 0.0% 4.5% 13.0% 20.0% 12.5% 13.8% Operating income 0.0% n.m. 6.9% -15.0% 78.2% 41.3% Net income/ loss 0.0% n.m. 39.0% -22.5% 68.5% 41.3% 1

3 BALANCE SHEET ANALYSS All figures in ' A 2008A 2009A 2010E Assets Current Assets, Total 15,798 15,709 17,873 23,420 Cash and Cash Equivalents 5,949 8,082 6,314 14,188 Trade accounts and notes receivables 4,760 5,713 10,569 7,428 Receivables to Associated Parites 2, nventories 2,353 1, ,421 Non-Current Assets, Total 7,368 9,160 10,868 9,519 Goodwill + ntangible Assets 5,639 7,526 9,504 8,867 Property, plant and Equipment Other Assets 1,270 1, Total Assets 23,166 24,869 28,741 33,739 Shareholders' Equity & Debt Current Liabilities, Total 10,622 7,297 9,559 7,781 Trade payables 3,294 2,536 3,862 3,263 Short Term Debt + CP of LTD 2, Current provisions 1,764 2,000 2,230 2,065 Short term finance leases ,054 0 Other current liabilities 3,429 2,097 2,413 2,453 Longterm Liabilities, Total 178 1, ,922 Long Term Debt Deferred Revenue ,453 Other Liabilities Shareholders Equity, Total 12,366 16,335 18,723 23,036 Share Capital 24,879 26,193 26,309 29,120 Capital Reserve 5,678 6,579 6,728 7,465 Other Reserves 1,869 2,120 2,154 2,240 Loss carryforward / retained eranings -20,060-18,557-16,468-15,789 Minority interests Total Consolidated Equity and Debt 23,166 24,869 29,068 33,739 Ratios Current ratio Quick ratio Equity ratio (as%) 53.4% 65.7% 63.3% 68.3% Debt to equity ratio (gearing as %) 1.4% 7.6% 4.2% 12.7% Equity per share Net cash 3,948 8,082 6,314 14,188 nterest coverage ratio Capital employed (CE) 11,274 16,405 18,389 25,158 Return on Equity (ROE) n.m Return on capital employed (ROCE) n.m 9.2% 11.4% 6.4% Return on net assets (RONA) n.m 6.0% 7.3% 4.8% Days of inventory turnover Days of sales outstanding (DSO)

4 CASH FLOW ANALYSS All figures in ' A 2008A 2009A 2010E 2011E 2012E Net ncome -2,033 1,503 2,089 1,619 2,727 3,854 Depreciation and amortization ,765 2,283 2,500 3,000 nvestment in working capital -6, ,485 2, Others 1, Operating Cashflow -6,330 3, ,561 5,227 6,854 CAPEX nvestments in ntangibles -30-2,106-2,505-1, Free cashflow -6, ,067 5,111 4,827 6,454 Debt Financing Equity Financing 5, , Other Changes in Cash 3,476 2, Change in Cash 2,320 2,132-1,767 9,096 5,227 6,854 Cash, start of the year 3,629 5,949 8,082 6,314 14,188 19,415 Cash, end of the year 5,949 8,082 6,314 14,188 19,415 26,269 Cashflow per share in Y-Y Growth Operating Cashflow 0.0% n.m % 693.3% -20.3% 31.1% Free cashflow 0.0% n.m. n.m. n.m. -5.5% 33.7% Cashflow per share 0.0% -9.3% n.m. n.m % 30.0% 3

5 FRST BERLN RECOMMENDATON & PRCE TARGET HSTORY Report No.: Date of publication Previous day closing price Recommendation Price target nitial Report 18 November Buy 2.60 nterim Update 18 November Buy Today 2.00 Buy 2.60 Disclaimer F R S T B E R L N D S C Tsvetan Kintisheff First Berlin Equity Research GmbH Mohrenstraße Berlin Tel. +49 (0) Fax +49 (0) info@firstberlin.com FRST BERLN POLCY n an effort to assure the independence of First Berlin research neither analysts nor the company itself trade or own securities in subject companies. n addition, analysts compensation is not directly linked to specific financial transactions, trading revenue or asset management fees. Analysts are compensated on a broad range of benchmarks. Furthermore, First Berlin receives no compensation from subject companies in relation to the costs of producing this report. ANALYST CERTFCATON, Tsvetan Kintisheff, certify that the views expressed in this report accurately reflect my personal and professional views about the subject company; and certify that my compensation is not directly linked to any specific financial transaction including trading revenue or asset management fees; neither is it directly or indirectly related to the specific recommendation or views contained in this research. n addition, possess no shares in the subject company. NVESTMENT RATNG SYSTEM First Berlin s investment rating system is five tiered and includes an investment recommendation and a risk rating. Our recommendations, which are a function of our expectation of total return (forecast price appreciation and dividend yield) in the year specified, are as follows: STRONG BUY: Expected return greater than 50% and a high level of confidence in management s financial guidance BUY: Expected return greater than 25% ADD: Expected return between 0% and 25% REDUCE: Expected negative return between 0% and -15% SELL: Expected negative return greater than -15% Our risk ratings are Low, Medium, High and Speculative and are determined by ten factors: corporate governance, quality of earnings, management strength, balance sheet and financing risk, competitive position, standard of financial disclosure, regulatory and political uncertainty, company size, free float and other company specific risks. These risk factors are incorporated into our valuation models and are therefore reflected in our price targets. Our models are available upon request to First Berlin clients. Up until 16 May 2008, First Berlin s investment rating system was three tiered and was a function of our expectation of return (forecast price appreciation and dividend yield) over the specified year. Our investment ratings were as follows: BUY: expected return greater than 15%; HOLD: expected return between 0% and 15%; and SELL: expected negative return. ADDTONAL DSCLOSURES This report is not constructed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer would be illegal. We are not soliciting any action based upon this material. This material is for the general information of clients of First Berlin. t does not take into account the particular investment objectives, financial situation or needs of individual clients. Before acting on any advice or recommendation in this material, a client should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. The material is based upon information that we consider reliable, but we do not represent that it is accurate or complete, and it should be relied upon as such. Opinions expressed are our current opinions as of the date appearing on this material only; such opinions are subject to change without notice. Copyright 2008 First Berlin Equity Research GmbH. All rights reserved. No part of this material may be copied, photocopied or duplicated in any form by any means or redistributed without First Berlin s prior written consent. The research is not for distribution in the USA or Canada. When quoting please cite First Berlin as the source. Additional information is available upon request. 4

5 November C Solarparken AG. FIRST BERLIN Equity Research

5 November C Solarparken AG. FIRST BERLIN Equity Research FIRST BERLIN Equity Research 5 7C Solarparken AG 7 RATING Germany / Cleantech Primary Exchange: Frankfurt Next growth phase PRICE TARGET 3.00 Bloomberg: HRPK GF Return Potential 30.4% ISIN: DE000A11QW68

More information

7C Solarparken GUIDANCE FOR 2016 INCREASED. FIRST BERLIN Equity Research. Preliminary 2014 PRICE TARGET 2.10

7C Solarparken GUIDANCE FOR 2016 INCREASED. FIRST BERLIN Equity Research. Preliminary 2014 PRICE TARGET 2.10 FIRST BERLIN Equity Research 12 7C Solarparken AG 7 RATING Germany / Cleantech Preliminary 2014 Primary Exchange: Frankfurt PRICE TARGET 2.10 Bloomberg: HRPK GF figures Return Potential 13.9% ISIN: DE000A11QW68

More information

25 April 2014 OpenLimit Holding AG. FIRST BERLIN Equity Research

25 April 2014 OpenLimit Holding AG. FIRST BERLIN Equity Research FIRST BERLIN Equity Research OpenLimit Holding AG RATING Switzerland / Software Primary exchange: Frankfurt FY 2013 figures PRICE TARGET 1.30 Bloomberg: O5H GR Return Potential 90.1% ISIN: CH0022237009

More information

Deutsche Biotech Innovativ AG

Deutsche Biotech Innovativ AG FIRST BERLIN Equity Research Deutsche Biotech Innovativ AG RATING Germany / Pharmaceutical/Biotechnology Düsseldorf Update PRICE TARGET 39.50 Bloomberg: VUA GR Return Potential 46.3% ISIN: DE000A0Z25L1

More information

SFC Energy AG STRONG GROWTH AND PROFITABILITY AHEAD. FIRST BERLIN Equity Research. Preliminary PRICE TARGET S F

SFC Energy AG STRONG GROWTH AND PROFITABILITY AHEAD. FIRST BERLIN Equity Research. Preliminary PRICE TARGET S F FIRST BERLIN Equity Research SFC Energy AG RATING Germany / Energy Preliminary Primary exchange: Frankfurt PRICE TARGET 8.70 Bloomberg: F3C GR 2017 figures Return Potential 13.3% ISIN: DE0007568578 Risk

More information

Intershop Communications AG

Intershop Communications AG FIRST BERLIN Equity Research Intershop Communications AG RATING GERMANY / Technology Primary Exchange: Frankfurt Q2 figures PRICE TARGET 1.44 Bloomberg: ISH2 GR Return Potential -15.2% ISIN: DE000A0EPUH1

More information

HAEMATO AG SOLID UPTICK IN H2 SALES AND EBIT MARGIN. FIRST BERLIN Equity Research PRICE TARGET H A

HAEMATO AG SOLID UPTICK IN H2 SALES AND EBIT MARGIN. FIRST BERLIN Equity Research PRICE TARGET H A FIRST BERLIN Equity Research HAEMATO AG RATING Germany / Pharma 2017 Frankfurt PRICE TARGET 7.40 Bloomberg: HAE GR Prelims Return Potential 25.4% ISIN: DE0006190705 Risk Rating High SOLID UPTICK IN H2

More information

CLERE AG DELISTING & TAKEOVER BID BY MAIN SHAREHOLDER. FIRST BERLIN Equity Research. Delisting & PRICE TARGET C L

CLERE AG DELISTING & TAKEOVER BID BY MAIN SHAREHOLDER. FIRST BERLIN Equity Research. Delisting & PRICE TARGET C L CLERE AG RATING Germany / Cleantech Delisting & Primary exchange: XETRA PRICE TARGET 16.33 Bloomberg: CAG GR takeover bid Return Potential 1.8% ISIN: DE0005215107 Risk Rating Medium DELISTING & TAKEOVER

More information

18 November 2016 Energiekontor AG. FIRST BERLIN Equity Research

18 November 2016 Energiekontor AG. FIRST BERLIN Equity Research FIRST BERLIN Equity Research Energiekontor AG RATING Germany / Cleantech Frankfurt Stock Exchange 9M report PRICE TARGET 19.70 Bloomberg: EKT GR Return Potential 31.3% ISIN: DE0005313506 Risk Rating High

More information

1 November 2017 M1 Kliniken AG. FIRST BERLIN Equity Research. Update following

1 November 2017 M1 Kliniken AG. FIRST BERLIN Equity Research. Update following FIRST BERLIN Equity Research M1 Kliniken AG RATING Germany / Healthcare Facilities & Services Update following Frankfurt PRICE TARGET 16.50 Bloomberg: M12 GR capital increase Return Potential 44.7% ISIN:

More information

18 October 2016 aventron AG. FIRST BERLIN Equity Research

18 October 2016 aventron AG. FIRST BERLIN Equity Research FIRST BERLIN Equity Research aventron AG RATING Switzerland / Renewable Energy Berner Börse H1 figures PRICE TARGET CHF13.00 Bloomberg: AVEN SW Return Potential 47.7% ISIN: CH0023777235 Risk Rating medium

More information

13 May 2016 PNE WIND AG. FIRST BERLIN Equity Research

13 May 2016 PNE WIND AG. FIRST BERLIN Equity Research FIRST BERLIN Equity Research PNE WIND AG RATING Germany / Cleantech Primary exchange: Frankfurt Q1/16 figures PRICE TARGET 3.30 Bloomberg: PNE3 GR Return Potential 50.1% ISIN: DE000A0JBPG2 Risk Rating

More information

14 September 2017 Pharming Group NV. FIRST BERLIN Equity Research. Update. Bloomberg: PHARM NA Return Potential 216.5% ISIN: NL

14 September 2017 Pharming Group NV. FIRST BERLIN Equity Research. Update. Bloomberg: PHARM NA Return Potential 216.5% ISIN: NL FIRST BERLIN Equity Research Pharming Group NV Netherlands / Biotechnology Primary exchange: Euronext Amsterdam / Secondary exchange: Frankfurt Update Bloomberg: PHARM NA Return Potential 216.5% ISIN:

More information

24 May 2016 Energiekontor AG. FIRST BERLIN Equity Research

24 May 2016 Energiekontor AG. FIRST BERLIN Equity Research FIRST BERLIN Equity Research Energiekontor AG RATING Germany / Cleantech Frankfurt Stock Exchange Q1 update PRICE TARGET 18.00 Bloomberg: EKT GR Return Potential 30.3% ISIN: DE0005313506 Risk Rating High

More information

27 March 2019 SFC Energy AG. FIRST BERLIN Equity Research. Final SUSTAINABLE MACRO TRENDS SUPPORT FUEL CELL BUSINESS

27 March 2019 SFC Energy AG. FIRST BERLIN Equity Research. Final SUSTAINABLE MACRO TRENDS SUPPORT FUEL CELL BUSINESS FIRST BERLIN Equity Research SFC Energy AG RATING Germany / Energy Final Primary exchange: Frankfurt PRICE TARGET 11.20 Bloomberg: F3C GR 2018 figures Return Potential 13.1% ISIN: DE0007568578 Risk Rating

More information

22 November 2017 Energiekontor AG. FIRST BERLIN Equity Research

22 November 2017 Energiekontor AG. FIRST BERLIN Equity Research FIRST BERLIN Equity Research Energiekontor AG RATING Germany / Cleantech Frankfurt Stock Exchange 9M report PRICE TARGET 24.80 Bloomberg: EKT GR Return Potential 75.1% ISIN: DE0005313506 Risk Rating High

More information

6 September 2016 aventron AG. FIRST BERLIN Equity Research

6 September 2016 aventron AG. FIRST BERLIN Equity Research FIRST BERLIN Equity Research aventron AG RATING Switzerland / Renewable Energy Berner Börse Capital increase PRICE TARGET CHF13.00 Bloomberg: AVEN SW Return Potential 52.8% ISIN: CH0023777235 Risk Rating

More information

5 September 2016 OTI Greentech AG. FIRST BERLIN Equity Research

5 September 2016 OTI Greentech AG. FIRST BERLIN Equity Research FIRST BERLIN Equity Research OTI Greentech AG RATING Germany / Cleantech Exchange: Duesseldorf Preliminary H1 figures PRICE TARGET 1.90 Bloomberg: NSA GR Return Potential 280.0% ISIN: DE000A0HNE89 Risk

More information

PNE WIND AG OFFSHORE PROJECT ATLANTIS I SOLD. FIRST BERLIN Equity Research. Good start to PRICE TARGET P N

PNE WIND AG OFFSHORE PROJECT ATLANTIS I SOLD. FIRST BERLIN Equity Research. Good start to PRICE TARGET P N FIRST BERLIN Equity Research PNE WIND AG RATING Germany / Cleantech Good start to Primary exchange: Frankfurt PRICE TARGET 3.00 Bloomberg: PNE3 GR the new year Return Potential 43.8% ISIN: DE000A0JBPG2

More information

20 April 2018 Energiekontor AG. FIRST BERLIN Equity Research

20 April 2018 Energiekontor AG. FIRST BERLIN Equity Research FIRST BERLIN Equity Research Energiekontor AG RATING Germany / Cleantech Frankfurt Stock Exchange 2017 final figures PRICE TARGET 23.50 Bloomberg: EKT GR Return Potential 72.2% ISIN: DE0005313506 Risk

More information

17 May 2016 ISARIA Wohnbau AG. FIRST BERLIN Equity Research

17 May 2016 ISARIA Wohnbau AG. FIRST BERLIN Equity Research FIRST BERLIN Equity Research ISARIA Wohnbau AG RATING Germany / Real estate Frankfurt Q1/16 Results PRICE TARGET 5.70 Bloomberg: IWB GR Return Potential 71.8% ISIN: DE000A1E8H38 Risk Rating High SLOW Q1

More information

18 January 2018 Pharming Group NV. FIRST BERLIN Equity Research. Update. Bloomberg: PHARM NA Return Potential 45.9% ISIN: NL

18 January 2018 Pharming Group NV. FIRST BERLIN Equity Research. Update. Bloomberg: PHARM NA Return Potential 45.9% ISIN: NL FIRST BERLIN Equity Research Pharming Group NV Netherlands / Biotechnology Primary exchange: Euronext Amsterdam / Secondary exchange: Frankfurt Update Bloomberg: PHARM NA Return Potential 45.9% ISIN: NL0010391025

More information

26 April 2017 aventron AG. FIRST BERLIN Equity Research

26 April 2017 aventron AG. FIRST BERLIN Equity Research FIRST BERLIN Equity Research aventron AG RATING Switzerland / Renewable Energy Berner Börse 2016 annual figures PRICE TARGET CHF 13.00 Bloomberg: AVEN SW Return Potential 42.9% ISIN: CH0023777235 Risk

More information

HAEMATO AG MARKET SHARE WIN IN PARALLEL IMPORT BUSINESS. FIRST BERLIN Equity Research H1/18 PRICE TARGET H A

HAEMATO AG MARKET SHARE WIN IN PARALLEL IMPORT BUSINESS. FIRST BERLIN Equity Research H1/18 PRICE TARGET H A FIRST BERLIN Equity Research HAEMATO AG RATING Germany / Pharma H1/18 Frankfurt PRICE TARGET 7.60 Bloomberg: HAE GR results Return Potential 41.8% ISIN: DE0006190705 Risk Rating High MARKET SHARE WIN IN

More information

Advanced Vision Technology

Advanced Vision Technology FIRST BERLIN Equity Research Advanced Vision Technology Ltd RATING Israel / Machine Vision Technology Q3/16 Primary exchange: Frankfurt PRICE TARGET 11.70 / $12.70 Bloomberg: VSJ GR Results Return Potential

More information

18 May 2018 Pharming Group NV. FIRST BERLIN Equity Research

18 May 2018 Pharming Group NV. FIRST BERLIN Equity Research FIRST BERLIN Equity Research Pharming Group NV 18 P ha Netherlands / Biotechnology RATING BUY Primary exchange: Euronext Amsterdam / Secondary exchange: Frankfurt Q1 results PRICE TARGET 2.00 Bloomberg:

More information

26 October 2017 Energiekontor AG. FIRST BERLIN Equity Research. Update. Bloomberg: EKT GR Return Potential 67.2% ISIN: DE

26 October 2017 Energiekontor AG. FIRST BERLIN Equity Research. Update. Bloomberg: EKT GR Return Potential 67.2% ISIN: DE FIRST BERLIN Equity Research Energiekontor AG RATING Germany / Cleantech Frankfurt Stock Exchange Update PRICE TARGET 25.00 Bloomberg: EKT GR Return Potential 67.2% ISIN: DE0005313506 Risk Rating High

More information

ad pepper media International N.V.

ad pepper media International N.V. FIRST BERLIN Equity Research ad pepper media International N.V. RATING The Netherlands / Internet Services Frankfurt Final 2017 figures PRICE TARGET 4.80 Bloomberg: APM GR Return Potential 30.4% ISIN:

More information

14 August 2017 PNE WIND AG. FIRST BERLIN Equity Research

14 August 2017 PNE WIND AG. FIRST BERLIN Equity Research FIRST BERLIN Equity Research PNE WIND AG RATING Germany / Cleantech Primary exchange: Frankfurt Q2 figures PRICE TARGET 3.50 Bloomberg: PNE3 GR Return Potential 33.5% ISIN: DE000A0JBPG2 Risk Rating High

More information

19 December 2016 NOXXON Pharma NV. FIRST BERLIN Equity Research. Cooperation

19 December 2016 NOXXON Pharma NV. FIRST BERLIN Equity Research. Cooperation FIRST BERLIN Equity Research NOXXON Pharma NV RATING Germany / Biotechnology Cooperation Paris PRICE TARGET 40.00 Bloomberg: ALNOX FP agreement closed Return Potential 81.9% ISIN: NL0012044762 Risk Rating

More information

24 September 2018 OpenLimit Holding AG. FIRST BERLIN Equity Research

24 September 2018 OpenLimit Holding AG. FIRST BERLIN Equity Research FIRST BERLIN Equity Research OpenLimit Holding AG RATING Switzerland / Software Primary exchange: Frankfurt H1 figures PRICE TARGET 0.50 Bloomberg: O5H GR Return Potential 72.4% ISIN: CH0022237009 Risk

More information

Schloss Wachenheim AG

Schloss Wachenheim AG FIRST BERLIN Equity Research Schloss Wachenheim AG RATING Germany / Food & beverages 2015/16 Annual Primary exchange: Frankfurt PRICE TARGET 17.60 Bloomberg: SWA GR Report Return Potential 16.6% ISIN:

More information

7 March 2017 Sirona Biochem Corp. FIRST BERLIN Equity Research FY16. PRICE TARGET C$0.95 Secondary: Quotation Board Frankfurt.

7 March 2017 Sirona Biochem Corp. FIRST BERLIN Equity Research FY16. PRICE TARGET C$0.95 Secondary: Quotation Board Frankfurt. FIRST BERLIN Equity Research Sirona Biochem Corp RATING Canada / Pharmaceutical/Biotechnology Primary: TSX Venture FY16 PRICE TARGET C$0.95 Secondary: Quotation Board Frankfurt Results Bloomberg: SBM CN

More information

6 June 2018 Formycon AG. FIRST BERLIN Equity Research. Germany / Biopharmaceuticals Xetra Bloomberg: FYB GR Return Potential 44.2% ISIN: DE000A1EWVY8

6 June 2018 Formycon AG. FIRST BERLIN Equity Research. Germany / Biopharmaceuticals Xetra Bloomberg: FYB GR Return Potential 44.2% ISIN: DE000A1EWVY8 FIRST BERLIN Equity Research Formycon AG RATING Germany / Biopharmaceuticals Xetra Q1 2018 results PRICE TARGET 53.00 Bloomberg: FYB GR Return Potential 44.2% ISIN: DE000A1EWVY8 Risk Rating High FORMYCON

More information

Aroundtown SA LATEST RUN RATES CONFIRM GROWTH PHASE. FIRST BERLIN Equity Research. Operational PRICE TARGET Ar ou

Aroundtown SA LATEST RUN RATES CONFIRM GROWTH PHASE. FIRST BERLIN Equity Research. Operational PRICE TARGET Ar ou FIRST BERLIN Equity Research Aroundtown SA RATING Germany / Real Estate Operational Frankfurt Stock Exchange PRICE TARGET 8.20 Bloomberg: AT1 GR update Return Potential 26.1% ISIN: LU1673108939 Risk Rating

More information

8 May 2018 Formycon AG. FIRST BERLIN Equity Research. Germany / Biopharmaceuticals Xetra Bloomberg: FYB GR Return Potential 36.3% ISIN: DE000A1EWVY8

8 May 2018 Formycon AG. FIRST BERLIN Equity Research. Germany / Biopharmaceuticals Xetra Bloomberg: FYB GR Return Potential 36.3% ISIN: DE000A1EWVY8 FIRST BERLIN Equity Research Formycon AG RATING Germany / Biopharmaceuticals Xetra 2017 annual report PRICE TARGET 52.00 Bloomberg: FYB GR Return Potential 36.3% ISIN: DE000A1EWVY8 Risk Rating High LOOKING

More information

11 January 2018 Deutsche Rohstoff AG. FIRST BERLIN Equity Research. Update. Bloomberg: DR0 GR Return Potential 40.2% ISIN: DE000A0XYG76

11 January 2018 Deutsche Rohstoff AG. FIRST BERLIN Equity Research. Update. Bloomberg: DR0 GR Return Potential 40.2% ISIN: DE000A0XYG76 FIRST BERLIN Equity Research Deutsche Rohstoff AG RATING Germany / Raw materials Frankfurt Update PRICE TARGET 29.30 Bloomberg: DR0 GR Return Potential 40.2% ISIN: DE000A0XYG76 Risk Rating High PRICE TARGET

More information

Chow Tai Fook (1929 HK)

Chow Tai Fook (1929 HK) Equity Research Consumer Discretionary Hold (maintained) Target price: HK$8.50 Albert Yip, CFA SFC CE No. ADT599 albertyip@gfgroup.com.hk +852 3719 1010 GF Securities (Hong Kong) Brokerage Limited 29-30/F,

More information

Deutsche Biotech Innovativ AG

Deutsche Biotech Innovativ AG FIRST BERLIN Equity Research Deutsche Biotech Innovativ AG RATING Germany / Pharmaceutical/Biotechnology Düsseldorf Update PRICE TARGET 43.60 Bloomberg: VUA GR Return Potential 55.7% ISIN: DE000A0Z25L1

More information

Advanced Vision Techn Buy

Advanced Vision Techn Buy 16/9/13 16/11/13 16/1/14 16/3/14 16/5/14 16/7/14 16/9/14 16/11/14 16/1/15 16/3/15 16/5/15 16/7/15 MATELAN Research Update Note Closing price as of 13/8/15: 9.16 14 August 215 Company / Sector Fair Value

More information

14 November 2018 M1 Kliniken AG. FIRST BERLIN Equity Research. H1/18 figures &

14 November 2018 M1 Kliniken AG. FIRST BERLIN Equity Research. H1/18 figures & FIRST BERLIN Equity Research M1 Kliniken AG RATING Germany / Healthcare Facilities & Services H1/18 figures & Frankfurt PRICE TARGET 19.20 Bloomberg: M12 GR capital increase Return Potential 57.4% ISIN:

More information

18 May 2018 Energiekontor AG. FIRST BERLIN Equity Research

18 May 2018 Energiekontor AG. FIRST BERLIN Equity Research FIRST BERLIN Equity Research Energiekontor AG RATING Germany / Cleantech Frankfurt Stock Exchange Q1 report PRICE TARGET 23.70 Bloomberg: EKT GR Return Potential 55.4% ISIN: DE0005313506 Risk Rating High

More information

Petro Rabigh Shutdown marred Q2 results

Petro Rabigh Shutdown marred Q2 results PETROR AB: Saudi Arabia US$5.07bn 17.4% US$11.19mn Market cap Free float Avg. daily volume RSI10 Vol th Target price n/a n/a Consensus price 32.18 48.3% over current Current price 21.70 as at 17/8/2011

More information

Fila Korea (081660) Widespread growth potential

Fila Korea (081660) Widespread growth potential Fila Korea (8166) BUY (Maintain), TP: W98, (Maintain) Stock price (Apr 26, KRW) 83,5 Yr to Sales OP EBT NP EPS % chg EBITDA P/E EV/EBITDA P/B ROE Market cap (USD mn) 697 Dec (W bn) (W bn) (W bn) (W bn)

More information

FIRST BERLIN. CCR Logistics Systems AG. Rating: Strong Buy 2005 Price Target: 9.33 Risk Rating: Medium. Update: FY2004 Results

FIRST BERLIN. CCR Logistics Systems AG. Rating: Strong Buy 2005 Price Target: 9.33 Risk Rating: Medium. Update: FY2004 Results 26 April 2005 Primary Exchange: Frankfurt General Standard Update: FY2004 Results Symbol: CCR ISIN: DE0007627200 Key Points published its FY04 figures on 15 March. Company revenues came in at 26.32m, an

More information

MATELAN Research. InVision 49.0 Buy. Excellent margin trend in Prelims. Update Note. 24 February Company / Sector Fair Value Recommendation

MATELAN Research. InVision 49.0 Buy. Excellent margin trend in Prelims. Update Note. 24 February Company / Sector Fair Value Recommendation Update Note Price as of 21/02/13: 4 24 February 2014 Company / Sector Fair Value Recommendation InVision 49.0 Buy Technology: Cloud Computing ( 34) (Buy) Excellent margin trend in Prelims Share price performance

More information

BDI BioEnergy Internat Buy

BDI BioEnergy Internat Buy 13/08/12 13/10/12 13/12/12 13/02/13 13/04/13 13/06/13 13/08/13 13/10/13 13/12/13 13/02/14 13/04/14 13/06/14 13/08/14 MATELAN Research Update Note Price as of 13/08/14: 10.29 14 August 2014 Company / Sector

More information

Almonty Industries inc.

Almonty Industries inc. FIRST BERLIN Equity Research Almonty Industries Inc. RATING Canada / Mining Toronto Q2 2017/18 results PRICE TARGET CAD 1.30 Bloomberg: AII CN Return Potential 150.0% ISIN: CA0203981034 Risk Rating High

More information

Company Overview. Industry Overview. Financial Performance

Company Overview. Industry Overview. Financial Performance Feb/15 Mar/15 Apr/15 May/15 Jun/15 Jul/15 Aug/15 Sep/15 Oct/15 Nov/15 Dec/15 Jan/16 Trade Wings Limited CMP: 105.00 January 29, 2016 Stock Details BSE code 509953 BSE ID TRADWIN Face value ( ) 10 No of

More information

16 April 2018 Epigenomics AG. FIRST BERLIN Equity Research. Update. Bloomberg: ECX Return Potential 96.9% ISIN: DE000A11QW50

16 April 2018 Epigenomics AG. FIRST BERLIN Equity Research. Update. Bloomberg: ECX Return Potential 96.9% ISIN: DE000A11QW50 FIRST BERLIN Equity Research Epigenomics AG RATING Germany / Pharmaceutical/Biotechnology Primary Exchange: Frankfurt Update PRICE TARGET 7.10 Bloomberg: ECX Return Potential 96.9% ISIN: DE000A11QW50 Risk

More information

9 November 2018 Valneva SE. FIRST BERLIN Equity Research

9 November 2018 Valneva SE. FIRST BERLIN Equity Research FIRST BERLIN Equity Research Valneva SE RATING France / Biotechnology Euronext Paris 9M/18 results PRICE TARGET 5.40 Bloomberg: VLA FP Return Potential 58.1% ISIN: FR0004056851 Risk Rating High 2018 PRODUCT

More information

Anta Sports (2020 HK)

Anta Sports (2020 HK) Equity Research Consumer Discretionary Anta Sports (2020 HK) Buy (maintained) Target price: HK$18.50 Strong FY14 results; order book momentum maintained FY14 results above expectation Net profit jumped

More information

KWG. Seeking balance between scale and profitability. March 27, 2018 Equity Research. Stock code: 1813.HK Rating: HOLD Price target (HK$) 12.

KWG. Seeking balance between scale and profitability. March 27, 2018 Equity Research. Stock code: 1813.HK Rating: HOLD Price target (HK$) 12. Equity Research Seeking balance between scale and profitability Downgrade to HOLD and revise down TP to HK$12.50: 2017 result missed our estimation; core net profit dropped by 19% YoY, expansion execution

More information

Goodbaby (1086 HK) Buy (maintained) Target price: HK$ H16 results miss, but margin expansion continues. Equity Research Consumer Discretionary

Goodbaby (1086 HK) Buy (maintained) Target price: HK$ H16 results miss, but margin expansion continues. Equity Research Consumer Discretionary Equity Research Consumer Discretionary Goodbaby (1086 HK) Buy (maintained) Target price: HK$4.20 1H16 results miss, but margin expansion continues Maintain Buy Net profit rose 21% YoY to HK$107m in 1H16,

More information

Chow Sang Sang (116 HK)

Chow Sang Sang (116 HK) Equity Research Consumer Discretionary Chow Sang Sang (116 HK) Hold (maintained) Target price: HK$14.00 1H16 China sales outperformed peers; still cautious on HK market Maintain Hold We revise down our

More information

Chow Tai Fook (1929 HK)

Chow Tai Fook (1929 HK) Equity Research Consumer Discretionary Chow Tai Fook (1929 HK) Accumulate Target price: HK$11.60 3QFY15 sales disappoint SSS plunge 21% YoY in HK and Macau The sluggish sales was attributable to protest

More information

Rajesh Exports (RJEX_IN) Earnings Update Report Consumer Discretionary: Gold Jewelry Manufacturer

Rajesh Exports (RJEX_IN) Earnings Update Report Consumer Discretionary: Gold Jewelry Manufacturer Monday, February 4, 2019 www.evaluateresearch.com Target Price Rs. 900.00 Current Price Rs. 598.00 Upside Potential 50% Market Cap. Shares Outstanding Rs. 176,802 mn US$ 2.47 bn 295.3 mn Free Float (FF

More information

Sunway Unlocking value in construction

Sunway Unlocking value in construction Equity Malaysia Real Estate 22 September 2014 Buy Price RM3.36 Target price RM4.20 Market data Bloomberg code SWB MK No. of shares (m) 1,723.5 Market cap (RMm) 5,790.3 52-week high/low (RM) 3.36 / 2.55

More information

Luk Fook (590 HK) Hold (maintained) Target price: HK$ In line results, 1QFY17 remains weak. Equity Research Consumer Discretionary.

Luk Fook (590 HK) Hold (maintained) Target price: HK$ In line results, 1QFY17 remains weak. Equity Research Consumer Discretionary. Equity Research Consumer Discretionary Luk Fook (590 HK) Hold (maintained) Target price: HK$16.50 In line results, 1QFY17 remains weak In line results Net profit slumped 41% YoY to HK$959m in 1QFY17, in

More information

Yansab Better than expected results

Yansab Better than expected results YANSAB AB: Saudi Arabia US$6.91bn 39.8% US$23.37mn Market cap Free float Avg. daily volume RSI10 Vol th Target price n/a n/a Consensus price 56.00 21.5% over current Current price 46.10 as at 9/2/2011

More information

28 March 2019 PAION AG. FIRST BERLIN Equity Research

28 March 2019 PAION AG. FIRST BERLIN Equity Research FIRST BERLIN Equity Research PAION AG RATING Germany / Biotechnology Frankfurt Prime Standard 2018 Annual Report PRICE TARGET 4.10 Bloomberg: PA8 GR Return Potential 88.5% ISIN: DE000A0B65S3 Risk Rating

More information

Company Overview. Financial Performance

Company Overview. Financial Performance Feb/15 Mar/15 Apr/15 May/15 Jun/15 Jul/15 Aug/15 Sep/15 Oct/15 Nov/15 Dec/15 Jan/16 CMP: 32.30 February 11, 2016 Stock Details BSE code 526558 BSE ID JAMEHOT Face value ( ) 10 No of shares (m) 8.0 52 week

More information

ISRA VISION Neutral

ISRA VISION Neutral Update Note Closing price as of 1/8/17: 142.8 4 September 217 Company / Sector Fair Value Recommendation ISRA VISION 128. Neutral Technology: Machine Vision ( 128.) (unchanged) Solid Q3 leaves company

More information

27 February 2018 OpenLimit Holding AG. FIRST BERLIN Equity Research. Smart Meter Gateway BENEFITING FROM DIGITISATION OF HEALTH AND ENERGY MARKETS

27 February 2018 OpenLimit Holding AG. FIRST BERLIN Equity Research. Smart Meter Gateway BENEFITING FROM DIGITISATION OF HEALTH AND ENERGY MARKETS FIRST BERLIN Equity Research OpenLimit Holding AG RATING Switzerland / Software Smart Meter Gateway Primary exchange: Frankfurt PRICE TARGET 0.60 Bloomberg: O5H GR roll-out to start soon Return Potential

More information

SABIC Overall strong performance

SABIC Overall strong performance SABIC AB: Saudi Arabia US$80.80bn 22.6% US$124.7mn Market cap Free float Avg. daily volume RSI10 Vol th Target price 126.0 24.75% over current Consensus price 125.6 24.4% over current Current price 101.0

More information

CR Lands. Winner of next 5 years, BUY. March 21, 2018 Equity Research. Stock code: 1109.HK Rating: BUY Price target (HK$) 34.74

CR Lands. Winner of next 5 years, BUY. March 21, 2018 Equity Research. Stock code: 1109.HK Rating: BUY Price target (HK$) 34.74 Equity Research Winner of next 5 years, BUY 2017 result: slow growth, but high profitability Revenue slightly improved by 8.5% YoY to HKD 118.5 bn. Thanks to GPM growing by 6.5 pts to 40%, gross profit

More information

Almonty Industries inc.

Almonty Industries inc. FIRST BERLIN Equity Research Almonty Industries Inc. RATING Canada / Mining Toronto Annual Report PRICE TARGET CAD 1.25 Bloomberg: AII CN Return Potential 92.3% ISIN: CA0203981034 Risk Rating High WEAKER

More information

Company Overview. Industry Overview. Financial Performance

Company Overview. Industry Overview. Financial Performance Jan/15 Feb/15 Mar/15 Apr/15 May/15 Jun/15 Jul/15 Aug/15 Sep/15 Oct/15 Nov/15 Dec/15 CMP: 27.80 January 20, 2016 Stock Details BSE code 534623 BSE ID JUPITERIN Face value ( ) 10 No of shares (m) 10 52 week

More information

12 December 2018 Pharming Group NV. FIRST BERLIN Equity Research. acute HAE therapies HEAD-TO-HEAD STUDY GIVES PHARMING NEW WEAPON AGAINST FIRAZYR

12 December 2018 Pharming Group NV. FIRST BERLIN Equity Research. acute HAE therapies HEAD-TO-HEAD STUDY GIVES PHARMING NEW WEAPON AGAINST FIRAZYR FIRST BERLIN Equity Research Pharming Group NV Netherlands / Biotechnology comparative study of RATING Primary exchange: Euronext Amsterdam / PRICE TARGET 2.00 Secondary exchange: Frankfurt Bloomberg:

More information

Sanghvi Movers Ltd. Results above estimates. Figure 1: Actual Vs Religare Estimates. Financial highlights. Valuations and Recommendation

Sanghvi Movers Ltd. Results above estimates. Figure 1: Actual Vs Religare Estimates. Financial highlights. Valuations and Recommendation Institutional Equity Research Key data 3 June 28 Sector Capital Goods Market Cap Rs9bn/US$.2bn 52 Wk H/L (Rs) 337/15.5 BSE Avg. daily vol. (6m) 4,437 BSE Code 5373 NSE Code SANGHVIMOV Bloomberg SGM IN

More information

MPH Mittelstaendische Pharma Holding AG M P

MPH Mittelstaendische Pharma Holding AG M P FIRST BERLIN Equity Research MPH Mittelstaendische Pharma Holding AG M P RATING Germany / Healthcare Frankfurt Q1/16 Update PRICE TARGET 4.90 Bloomberg: 93M GR Return Potential 85.3% ISIN: DE000A0NF697

More information

AutoZone, Inc. EQUITY RESEARCH QUARTERLY UPDATE OUTPERFORM. Quick Read: Sales a Bit Soft, But Results Solid. September 22, 2016

AutoZone, Inc. EQUITY RESEARCH QUARTERLY UPDATE OUTPERFORM. Quick Read: Sales a Bit Soft, But Results Solid. September 22, 2016 EQUITY RESEARCH QUARTERLY UPDATE September 22, 2016 Stock Rating: OUTPERFORM 12-18 mo. Price Target $900.00 AZO - NYSE $751.45 3-5 Yr. EPS Gr. Rate 14% 52-Wk Range $819.54-$681.01 Shares Outstanding 30.8M

More information

China TCM (570 HK) Buy (maintained) Target price: HK$ H17 earnings beat, 2017 growth guidance reaffirmed; TP raised to HK$5.

China TCM (570 HK) Buy (maintained) Target price: HK$ H17 earnings beat, 2017 growth guidance reaffirmed; TP raised to HK$5. Oct-14 Dec-14 Feb-15 Apr-15 Jun-15 Aug-15 Oct-15 Dec-15 Feb-16 Apr-16 Jun-16 Aug-16 Oct-16 Dec-16 Feb-17 Apr-17 Jun-17 Equity Research Healthcare China TCM (570 HK) Buy (maintained) Target price: HK$5.40

More information

European Lithium Limited

European Lithium Limited FIRST BERLIN Equity Research European Lithium Limited RATING Australia / Mining Frankfurt, Sydney, Vienna Update PRICE TARGET 0.22 Bloomberg: PF8 GR Return Potential 120.0% ISIN: AU000000EUR7 Risk Rating

More information

Company Overview. Financial Performance

Company Overview. Financial Performance Jan/15 Feb/15 Mar/ Apr/15 May/ Jun/15 Jul/15 Aug/15 Sep/15 Oct/15 Nov/ Dec/15 Parnax Lab Limited CMP: 53.90 January 08, 2016 Stock Details BSE code 506128 BSE ID PARNAXLAB Face value ( ) 10 No of shares

More information

Sunway. Another feather to its cap

Sunway. Another feather to its cap Equity Malaysia Real Estate 20 March 2013 Buy Price RM2.74 Target price RM3.70 Market data Bloomberg code Performance 1M 3M 12M Absolute (%) 11 18 3 Rel market (%) 11 21 (0) 3.10 2.90 2.70 2.50 2.30 2.10

More information

Gujarat Alkalies and Chemicals Ltd

Gujarat Alkalies and Chemicals Ltd Gujarat Alkalies and Chemicas Ltd. is a Caustic Soda Manufacturer based in the state of Gujarat. It was set up in 1973 and is owned and operated by the Gujarat State Government. The company currently has

More information

Very solid Q3; excellent story, but priced in; TP upped to 60.00; downgrade to neutral. Q3 2016: Very solid quarter, better than expected

Very solid Q3; excellent story, but priced in; TP upped to 60.00; downgrade to neutral. Q3 2016: Very solid quarter, better than expected B a sl er A G # $T ypcap$ 1576 14 1 1 x 6495 2 Page 1/6 First Take Reco. lowered Neutral vs Buy Electronics Germany Neutral Target price : 60.00 EUR vs 52.00 EUR Price (11/01/2016) : 58.04 EUR Upside :

More information

Aroundtown Property Holdings Plc.

Aroundtown Property Holdings Plc. FIRST BERLIN Equity Research Aroundtown Property Holdings Plc. RATING Germany / Real Estate Q1/17 Frankfurt Stock Exchange PRICE TARGET 6.40 Bloomberg: AT1 GR Results Return Potential 38.5% ISIN: CY0105562116

More information

Kingsoft (3888 HK) Buy (maintained) Target price: HK$ Strong earnings recovery ahead amid continued revenue momentum; maintain Buy

Kingsoft (3888 HK) Buy (maintained) Target price: HK$ Strong earnings recovery ahead amid continued revenue momentum; maintain Buy Equity Research Information Technology Mar 29, 216 Kingsoft (3888 HK) Buy (maintained) Target price: HK$24.7 Strong earnings recovery ahead amid continued revenue momentum; maintain Buy FY1 results in

More information

O'Reilly Automotive, Inc. Quick Read: Weather Likely Weighed Upon Sales a Bit

O'Reilly Automotive, Inc. Quick Read: Weather Likely Weighed Upon Sales a Bit EQUITY RESEARCH QUARTERLY UPDATE July 27, 2016 Stock Rating: OUTPERFORM 12-18 mo. Price Target $300.00 ORLY - NASDAQ $277.51 3-5 Yr. EPS Gr. Rate 18% 52-Wk Range $284.66-$225.12 Shares Outstanding 99.4M

More information

TCL Communication (2618 HK) Painful transition period. Buy (Maintain) Target Price HK$2.33 Up/downside +28.5% Current price HK$1.

TCL Communication (2618 HK) Painful transition period. Buy (Maintain) Target Price HK$2.33 Up/downside +28.5% Current price HK$1. Securities Analysis (Equity) TCL Communication (218 HK) Painful transition period 1H12 profit warning. TCL Com announced profit warning on 15 Jul and expected to record a significant drop in 2Q12 net profit

More information

Kingsoft (3888 HK) Buy (maintained) Target price: HK$ Q16 results in line, renewed growth outlook; maintain Buy with target price of HK$20.

Kingsoft (3888 HK) Buy (maintained) Target price: HK$ Q16 results in line, renewed growth outlook; maintain Buy with target price of HK$20. Equity Research Information Technology Kingsoft (3888 HK) Buy (maintained) Target price: HK$2.77 2Q16 results in line, renewed growth outlook; maintain Buy with target price of HK$2.77 2Q16 results in

More information

Luk Fook (590 HK) Hold Target price: HK$ Downgrade to Hold on more challenging HK & Macau market outlook. Equity Research Consumer Discretionary

Luk Fook (590 HK) Hold Target price: HK$ Downgrade to Hold on more challenging HK & Macau market outlook. Equity Research Consumer Discretionary Equity Research Consumer Discretionary Luk Fook (590 HK) Hold Target price: HK$24.60 Albert Yip, CFA SFC CE No. ADT599 albertyip@gfgroup.com.hk +852 3719 1010 GF Securities (Hong Kong) Brokerage Limited

More information

Simmtech (222800) Focus on 2H earnings WHAT S THE STORY?

Simmtech (222800) Focus on 2H earnings WHAT S THE STORY? Company Update Simmtech (222800) Focus on 2H earnings Simmtech yesterday reported disappointing 4Q results, which compels us to cut our 2018 operating profit forecast by 10% to KRW52.9b and 12-month target

More information

4 July 2017 PAION AG. FIRST BERLIN Equity Research. Update. Bloomberg: PA8 GR Return Potential 44.5% ISIN: DE000A0B65S3

4 July 2017 PAION AG. FIRST BERLIN Equity Research. Update. Bloomberg: PA8 GR Return Potential 44.5% ISIN: DE000A0B65S3 FIRST BERLIN Equity Research PAION AG RATING Germany / Biotechnology Frankfurt Prime Standard Update PRICE TARGET 4.40 Bloomberg: PA8 GR Return Potential 44.5% ISIN: DE000A0B65S3 Risk Rating High REMIMAZOLAM

More information

Anta Sports (2020 HK)

Anta Sports (2020 HK) Equity Research Consumer Discretionary Anta Sports (2020 HK) Hold (downgraded) Target price: HK$22.80 Albert Yip, CFA SFC CE No. ADT599 albertyip@gfgroup.com.hk +852 3719 1010 GF Securities (Hong Kong)

More information

Luk Fook (590 HK) Hold (downgraded) Target price: HK$ HFY18 results beat, but downgrade from Accumulate to Hold on rich valuation

Luk Fook (590 HK) Hold (downgraded) Target price: HK$ HFY18 results beat, but downgrade from Accumulate to Hold on rich valuation Equity Research Consumer Discretionary Luk Fook (590 HK) Hold (downgraded) Target price: HK$34.80 Albert Yip, CFA SFC CE No. ADT599 albertyip@gfgroup.com.hk +852 3719 1010 GF Securities (Hong Kong) Brokerage

More information

Indygotech Minerals S.A.

Indygotech Minerals S.A. Indygotech Minerals S.A. Fair Value: n.a. Update Rating: n.a Indygotech Minerals (IDG) share price has recently taken a hit. The reason was a delay of completion of the production facilities for ceramic

More information

Zain KSA bogged down by high debt

Zain KSA bogged down by high debt Vol th RSI10 Zain KSA ZAINKSA AB: Saudi Arabia US$2.464bn 48.3% US$16.50mn Market cap Free float Avg. daily volume Target price 7.30 12.31% over current Consensus price 7.62 17.2% over current Current

More information

Gaiam, Inc. Gaiam, Inc. Financial Snapshot. Operating Performance. Fast Facts. SWOT Analysis. [Figure] Gaiam, Inc. - SWOT Profile Page 1

Gaiam, Inc. Gaiam, Inc. Financial Snapshot. Operating Performance. Fast Facts. SWOT Analysis. [Figure] Gaiam, Inc. - SWOT Profile Page 1 Gaiam, Inc. Fast Facts Headquarters Address Telephone Fax Website Ticker Symbol, Stock Exchange Financial Snapshot Operating Performance The company reported revenue of US$XX million during the fiscal

More information

Zain KSA restructuring ensures fresh start

Zain KSA restructuring ensures fresh start Vol mn RSI10 Zain KSA ZAINKSA AB: Saudi Arabia US$5.41bn 48.3% US$142.1mn Market cap Free float Avg. daily volume Target price 15.90 9.68% over current Consensus price 16.10 11.0% over current Current

More information

Company Overview. Financial Performance

Company Overview. Financial Performance Apr/15 May/15 Jun/15 Jul/15 Aug/15 Sep/15 Oct/15 Nov/15 Dec/15 Jan/16 Feb/16 Mar/16 Monarch Networth Capital Limited CMP: 26.00 March 23, 2016 Stock Details BSE code 511551 BSE ID MONARCH Face value (

More information

HOLD. Deleveraging story playing out RAMCO CEMENTS. Target Price: Rs 503. Q4 performance

HOLD. Deleveraging story playing out RAMCO CEMENTS. Target Price: Rs 503. Q4 performance RAMCO S HOLD Target Price: Rs 503 Deleveraging story playing out Ramco Cements total debt reduced by a massive Rs 5 bn to Rs 22 bn in FY16. The company generated total EBITDA of Rs 11.5 bn in FY16 and

More information

Company Overview. Financial Performance

Company Overview. Financial Performance Dec-14 Jan-15 Feb-15 Mar-15 Apr-15 May-15 Jun-15 Jul-15 Aug-15 Sep-15 Oct-15 Nov-15 Nimbus Projects Limited CMP: 34. December 4, 15 Stock Details BSE code 511714 BSE ID NIMBSPROJ Face value ( ) 1 No of

More information

China Renewable Energy Investment Ltd (987_HK)

China Renewable Energy Investment Ltd (987_HK) Wednesday, March 21, 2018 www.evaluateresearch.com Target Price HK$ 0.50 Current Price HK$ 0.23 Upside Potential 117% Market Cap. Shares Outstanding HK$ 525 mn $ 66.90 mn 2,364.7 mn Free Float (FF %) 631.9

More information

Dr Reddy s Laboratories

Dr Reddy s Laboratories : price: EPS: How does our one year outlook change? We maintain rating on DRRD post the company s 3QFY16 results Revenue growth for the quarter was muted (3% yoy) due to disappointing performances in Russia

More information

co.don AG Q1 substantially above last year 13 April 2015

co.don AG Q1 substantially above last year 13 April 2015 13 April 2015 co.don AG Reuters: CNWK.DE Bloomberg: CNWK:GR Q1 substantially above last year Rating: Buy Price: EUR 2.88 Price target: EUR 4.20 Risk: Medium Q1/2015 at a glance In the first quarter 2015,

More information

IFRS Financial Ratios

IFRS Financial Ratios 100 IFRS Financial Ratios Authors Ulrich Wiehle Michael Diegelmann Henryk Deter Dr. Peter Noel Schömig Michael Rolf 100 IFRS Financial Ratios cometis publishing GmbH & Co. KG, Unter den Eichen 7, 65195

More information

28,491 PRICE: HK$ EARNINGS

28,491 PRICE: HK$ EARNINGS 2 Recommendation: BUY TP: HK$139 (+18.1%) VTech Holdings Ltd (303.HK) 11 October 2017 SECTOR: Communications Equipment HSI: 28,491 PRICE: HK$117.70 EARNINGS (reported in USDm) KEY DATA For the fiscal year

More information